新诊断导管原位癌的术前乳腺MRI:多中心环境下的影像特征与效能(ECOG-ACRIN E4112试验)
基于ECOG-ACRIN E4112多中心前瞻性试验的二次分析,纳入339例经传统影像(乳腺X线和超声)诊断、空心针活检证实的导管原位癌(DCIS)女性,评估术前MRI的影像特征与效能。结果示多数DCIS表现为非肿块强化(58%),MRI中位大小19 mm大于乳腺X线的12 mm(P < .001);MRI提示的空心针活检阳性预测值为32%,额外癌症检出率6.2%,假阳性率14.2%;无影像特征与浸润升级或DCIS评分相关(P = .05至P = .95);MRI上较小尺寸和局灶性非肿块强化分布与单次保乳手术成功相关(P < .001)。
要点
- MRI上DCIS多表现为非肿块强化(195/339,58%),中位大小19 mm大于乳腺X线的12 mm(P < .001)。
- MRI提示的空心针活检阳性预测值为32%(21/66,95% CI:22,44),额外癌症检出率为6.2%(21/339,95% CI:4.1,9.3),假阳性率为14.2%(45/318,95% CI:10.7,18.4)。
- 无影像特征与浸润升级或DCIS评分(<39 vs ≥39)相关(P = .05至P = .95);MRI上较小尺寸和局灶性非肿块强化分布与单次保乳手术成功相关(P < .001)。
核心结论
- 术前MRI将传统影像诊断的DCIS最常见表现为非肿块强化,中位跨度大于乳腺X线,额外癌症检出率6.2%;该DCIS亚群的MRI特征未能预测病理或基因组结局。
研究设计与样本
- ECOG-ACRIN E4112多中心前瞻性临床试验的二次分析,纳入2015年3月至2016年4月入组、经乳腺X线和超声诊断并经空心针活检证实、基于传统影像和临床检查适合广泛局部切除的339例DCIS女性(中位年龄60岁,四分位距51-66岁),记录MRI和病理特征,对未发生浸润升级者计算12基因DCIS评分。
关键影像表现/征象
- 多数DCIS在MRI上表现为非肿块强化(195/339,58%),MRI中位大小19 mm大于乳腺X线的12 mm(P < .001)。
诊断标准与关键数值
- MRI提示的空心针活检阳性预测值为32%(21/66,95% CI:22,44),额外癌症检出率为6.2%(21/339,95% CI:4.1,9.3),MRI假阳性率为14.2%(45/318,95% CI:10.7,18.4)。
- 无影像特征与浸润升级或DCIS评分(<39 vs ≥39)相关(P = .05至P = .95);MRI上较小尺寸和局灶性非肿块强化分布与单次广泛局部切除成功相关(P < .001)。
临床应用与阅片要点
- 术前MRI可显示传统影像诊断的DCIS,最常见为非肿块强化,且中位跨度大于乳腺X线,额外癌症检出率为6.2%。
- 本DCIS亚群的MRI特征未能预测病理或基因组结局(P = .05至P = .95)。
- MRI上较小尺寸和局灶性非肿块强化分布与单次广泛局部切除成功相关(P < .001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background There are limited data from clinical trials describing preoperative MRI features and performance in the evaluation of mammographically detected ductal carcinoma in situ (DCIS). Purpose To report qualitative MRI features of DCIS, MRI performance in the identification of additional disease, and associations of imaging features with pathologic, genomic, and surgical outcomes from the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E4112 trial. Materials and Methods Secondary analyses of a multicenter prospective clinical trial from the ECOG-ACRIN Cancer Research Group included women with DCIS diagnosed with conventional imaging techniques (mammography and US), confirmed via core-needle biopsy (CNB), and enrolled between March 2015 and April 2016 who were candidates for wide local excision (WLE) based on conventional imaging and clinical examination results. DCIS MRI features and pathologic features from CNB and excision were recorded. Each woman without invasive upgrade of the index DCIS at WLE received a 12-gene DCIS score. MRI performance metrics were calculated. Associations of imaging features with invasive upgrade, dichotomized DCIS score (<39 vs ≥39), and single WLE success were estimated in uni- and multivariable analyses. Results Among 339 women (median age, 60 years; interquartile range, 51-66 years), most DCIS cases showed nonmass enhancement (NME) (195 of 339 [58%]) on MRI scans with larger median size than on mammograms (19 mm vs 12 mm; P < .001). Positive predictive value of MRI-prompted CNBs was 32% (21 of 66) (95% CI: 22, 44), yielding an additional cancer detection rate of 6.2% (21 of 339) (95% CI: 4.1, 9.3). MRI false-positive rate was 14.2% (45 of 318) (95% CI: 10.7, 18.4). No imaging features were associated with invasive upgrade or DCIS score (P = .05 to P = .95). Smaller size and focal NME distribution at MRI were linked to single WLE success (P < .001). Conclusion Preoperative MRI depicted ductal carcinoma in situ (DCIS) diagnosed with conventional imaging most commonly as nonmass enhancement, with larger median span than mammography, and additional cancer detection rate of 6.2%. MRI features of this subset of DCIS did not enable prediction of pathologic or genomic outcomes. Clinical trial registration no. NCT02352883 © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Kuhl in this issue. An earlier incorrect version of this article appeared online. This article was corrected on August 4, 2021.
引用
- Chou SS, Romanoff J, Lehman CD, et al. Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). Radiology. 2021. PMID: 34342501. doi:10.1148/radiol.2021204743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。